OPENING KEYNOTE ADDRESS
Wednesday, May 10, 9:00AM
Author of five bestsellers, David and Goliath, What the Dog Saw, Outliers, Blink, and The Tipping Point.
Provocative ideas taking the business world by storm. Phenomenal best-selling author.
An incomparable gift for making new ideas in the social sciences understandable, practical and valuable to both business and general audiences. Author of four perennial bestsellers including The Tipping Point, 400+ weeks on the New York Times bestseller list and now, his latest, David and Goliath: Underdogs, Misfits and the Art of Battling Giants. He has been named one of the 100 most influential people by TIME magazine and one of the Foreign Policy’s Top Global Thinkers.
He has explored how ideas spread in The Tipping Point, decision making in Blink, and the roots of success in Outliers. With his latest book, David and Goliath, he examines our understanding of the advantages of disadvantages, arguing that we have underestimated the value of adversity and over-estimated the value of privilege.
Malcolm’s next book was actually a 10-part podcast titled Revisionist History. In the weekly podcast, Malcolm re-examined an overlooked or misunderstood aspect of past events.
He has been a staff writer for The New Yorker since 1996. He has won a national magazine award and been honored by the American Psychological Society and the American Sociological Society. He was previously a reporter for The Washington Post.
Malcolm is an extraordinary speaker: always on target, aware of the context and the concerns of the audience, informative and practical, poised, eloquent and warm and funny. He has an unsurpassed ability to be both entertaining and challenging.
The NewYorkBIO 2017 Annual Conference will take place May 10-11, 2017, at 10 on the the Park @ Time Warner Center in Columbus Circle.
Each year the event draws over 1,000 attendees from New York and across the Northeast, as well as a global audience including attendees from Europe and Asia.
The theme of the 2017 Annual Conference is "New York Life Science at a Tipping Point."
Over the past several years, the New York life science ecosystem has seen huge growth in industry development, venture investment, commercial expansion, and patient relations. But it has taken a long time to get this point, and the industry has had some significant set backs. The 2017 Annual Conference will therefore be a frank and open discussion of the issues—the good, the bad, and the ugly—of New York’s life science scene as it exists today and what may be the strengths, weaknesses, opportunities, and threats to it. What have we done right? What have we done wrong? What lessons can be learned and applied?
The Annual Conference will address these questions through four major areas:
1 Technology and Biotechnology: the NY digital health community and its relationship to the bioscience community; the intersection of devices/diagnostics/ therapeutics/etc; wearables; the state and future medical devices and diagnostics; bioscience in the cloud; data and big data; etc.
2 Academy/Industry/Government Partnership and Leadership: new models in industry/academic collaboration (e.g., Bridge Medicine); financing models; public/private partnerships in an era of small government; innovative partnership development opportunities and trends; what works, what doesn't; etc.
3 The Science and Business of Business and Science: innovative development collaboration models and partnering trends; successful business development and research initiatives; "pre-competitive" collaboration driving longer-term discovery goals; the role of foundations and patient advocates; innovation and financing; "wellness" and “health-tech”; etc.
4 Policy, Legal and Regulatory Challenges: innovation and pricing; the “Trump FDA”; PDUFA VI; impact and outlook for 21st Century Cures Act; reimbursement for innovation; “ACA reform” and its impact on NY; patient-centric policy; etc.
Who should attend?
The NewYorkBIO Annual Conference is the official meeting of the Association, bringing together emerging and established companies, investors, business development professionals, scientists and others supporting and advancing life science discoveries. The attendees are:
- Emerging company executives
- Biopharma business development executives
- Members of the financial community
- Venture capitalists, angels and strategic investors
- Members of the professional advisory community
- Academic PIs & industry researchers